Industry news
Serious Fraud Office in UK to investigate GSK commercial operations
GlaxoSmithKline plc (GSK) has been informed by the UK's Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group's commercial practices. GSK states that it is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO. The decision by the SFO is likely to be related to allegations against GSK in overseas markets, particularly China, which could expose the company to charges under the UK Bribery Act.